Patents by Inventor Douglas Alan Lorenz

Douglas Alan Lorenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of enzalutamide
    Patent number: 11839689
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: December 12, 2023
    Assignees: Astellas Pharma Inc., Medivation Prostate Therapeutics LLC
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Formulations of Enzalutamide
    Publication number: 20230210778
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: July 6, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20230122911
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: April 20, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20200060976
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 27, 2020
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Compositions and methods for the treatment of neurodegenerative and other diseases
    Patent number: 10398713
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: September 3, 2019
    Assignee: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20190209476
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: July 11, 2019
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases
    Publication number: 20190015431
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: April 17, 2018
    Publication date: January 17, 2019
    Applicant: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
    Patent number: 10098843
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: October 16, 2018
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • Compositions and methods for the treatment of neurodegenerative and other diseases
    Patent number: 9980978
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: May 29, 2018
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Compositions and methods for the treatment of neurodegenerative and other diseases
    Patent number: 9974798
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: May 22, 2018
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Compositions and methods for the treatment of neurodegenerative and other diseases
    Patent number: 9918997
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: March 20, 2018
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170224624
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases
    Publication number: 20170165279
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 15, 2017
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES
    Publication number: 20170079990
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES
    Publication number: 20170079991
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Compositions and methods for the treatment of neurodegenerative and other diseases
    Patent number: 9597339
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 21, 2017
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170027910
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: February 8, 2016
    Publication date: February 2, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE
    Publication number: 20160213618
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Application
    Filed: January 21, 2016
    Publication date: July 28, 2016
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
    Patent number: 9241924
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 26, 2016
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140378517
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi